H.C. Wainwright downgraded Aadi Bioscience to Neutral from Buy without a price target after the company announced the initial interim results from the PRECISION 1 trial that is investigating Fyarro in patients harboring TSC1 and TSC2 inactivating alterations. The extremely advanced nature of these patient populations could be having a detrimental impact on the response rate, the analyst tells investors in a research note. After considering the initial interim data in both TSC1- and TSC2-altered solid tumors, the historical tumor agnostic approval benchmarks, and the likelihood that Fyarro would be reserved for later-line patients should the drug eventually be approved in a tumor-agnostic fashion, the firm downgraded the shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on AADI:
- Aadi Bioscience’s nab-sirolimus shows anti-tumor activity in interim trial
- Aadi Bioscience price target lowered to $36 from $45 at H.C. Wainwright
- Aadi Bioscience Reports Financial Results for the Third Quarter 2023 and Provides Corporate Update
- Aadi Bioscience reports Q3 EPS (60c), consensus (72c)
- Aadi Bioscience management to meet virtually with Jefferies